Pay in 4 interest-free payments of $6.61 Learn more
Ships within 48 hours · Estimated delivery Nov 9 - Nov 14
Vinchi F
Targeted research for patients with type 2 diabetes mellitus (T2DM) and obesity should focus on defining cancer risk epigenomic and genomic signatures
Intended Use: Laboratory research use only
Phase 2 data published in the New England Journal of Medicine (2023) demonstrated substantial weight loss in adults with obesity, but the medicine is not yet approved for clinical use in the UK
Importantly, GLUD1 inhibition through MLipRIR-NPs treatment has been shown to facilitate dendritic cell maturation, a process essential for antigen presentation and immune cell activation [206]
Nat Rev Mol Cell Biol 13 , 115126, (2012)
US$ 24.14
US$ 23.52
US$ 20.40
US$ 26.80
US$ 24.26
